BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12895392)

  • 1. Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia.
    Yin JA; Frost L
    Curr Oncol Rep; 2003 Sep; 5(5):399-404. PubMed ID: 12895392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21).
    Kwong YL; Chan V; Wong KF; Chan TK
    Cancer; 1995 Feb; 75(3):821-5. PubMed ID: 7828132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
    Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K
    Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative detection of AML1-ETO rearrangement by real-time RT-PCR using fluorescently labeled probes.
    Barragán E; Bolufer P; Moreno I; Martín G; Nomdedeu J; Brunet S; Fernández P; Rivas C; Sanz MA
    Leuk Lymphoma; 2001 Aug; 42(4):747-56. PubMed ID: 11697505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
    Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
    Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
    Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
    Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia.
    Matsuo H; Iijima-Yamashita Y; Yamada M; Deguchi T; Kiyokawa N; Shimada A; Tawa A; Tomizawa D; Taga T; Kinoshita A; Adachi S; Horibe K
    Pediatr Int; 2018 Jan; 60(1):41-46. PubMed ID: 29067751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Mrózek K; Prior TW; Edwards C; Marcucci G; Carroll AJ; Snyder PJ; Koduru PR; Theil KS; Pettenati MJ; Archer KJ; Caligiuri MA; Vardiman JW; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2001 May; 19(9):2482-92. PubMed ID: 11331327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical features and prognosis of core binding factor acute myeloid leukemia children in South China: a multicenter study].
    Guo BY; Wang Y; Li J; Li CF; Feng XQ; Zheng MC; Liu SX; Yang LH; Jiang H; Xu HG; He XL; Wen H
    Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):881-888. PubMed ID: 37803854
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnosis and monitoring of AML1-MTG8 (ETO)-positive acute myeloid leukemia by qualitative and real-time quantitative RT-PCR.
    Tobal K; Liu Yin JA
    Methods Mol Med; 2006; 125():149-61. PubMed ID: 16502583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
    Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X
    Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.
    Inokuchi K; Iwakiri R; Futaki M; Hanawa H; Tanosaki S; Nomura T; Dan K
    Leuk Lymphoma; 1998 May; 29(5-6):553-61. PubMed ID: 9643569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.
    Marcucci G; Livak KJ; Bi W; Strout MP; Bloomfield CD; Caligiuri MA
    Leukemia; 1998 Sep; 12(9):1482-9. PubMed ID: 9737700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
    Marcucci G; Caligiuri MA; Bloomfield CD
    Eur J Haematol; 2003 Sep; 71(3):143-54. PubMed ID: 12930314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of aml-1/eto fusion gene in patients with acute myeloid leukemia by real-time quantitative RT-PCR].
    Jiang YM; Yuan H; Liu XY; Wang B; Li SJ; Wang N
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):17-22. PubMed ID: 19236739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
    Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
    Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
    Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
    Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.